
Amgen Inc
AMGNHealthcare|Drug Manufacturers - General|USA
$342.57
-5.37 (-1.54%)
DCF (FCF)
$219.78
Earnings Power
$83.10
Clinical Trials (540)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06072482 A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | P4 | Recruiting | 300 | RCT, Double-blind | Avacopan, Placebo, Standard of Care |
| NCT06588153 A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China | Glucocorticoid-induced Osteoporosis | P4 | Recruiting | 100 | Open-label | Prolia® |
| NCT07037459 Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction | P3 | Recruiting | 5,056 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT04934475 MInimal Residual Disease Adapted Strategy | Multiple Myeloma | P3 | Active | 791 | RCT, Open-label | Isatuximab |
| NCT05565560 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | P3 | Active | 17 | Open-label | Apremilast |
| NCT04528082 Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | Behçet Disease | P3 | Recruiting | 60 | RCT, Double-blind | Apremilast, Placebo |
| NCT05111626 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P3 | Active | 515 | RCT, Double-blind | Bemarituzumab, Nivolumab, Chemotherapy |
| NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Active | 2,621 | RCT, Double-blind | Rocatinlimab |
| NCT06117774 Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | P3 | Recruiting | 400 | RCT, Double-blind | Tarlatamab, Placebo |
| NCT04307576 A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Leukemia, Acute Lymphoblastic | P3 | Recruiting | 6,430 | RCT, Open-label | Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab |
| NCT04483739 Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | Multiple Myeloma | P3 | Active | 302 | RCT, Open-label | Carfilzomib Lenalidomide Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone |
| NCT04303780 Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | P3 | Active | 345 | RCT, Open-label | AMG 510, Docetaxel |
| NCT04804553 Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis | Active Juvenile Psoriatic Arthritis | P3 | Recruiting | 60 | RCT, Double-blind | Apremilast, Placebo |
| NCT06883305 A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Chronic Obstructive Pulmonary Disease (COPD) | P3 | Recruiting | 990 | RCT, Double-blind | Tezepelumab |
| NCT07226765 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Obstructive Sleep Apnea | P3 | Recruiting | 250 | RCT, Double-blind | Maridebart cafraglutide, Placebo |
| NCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | P3 | Active | 368 | RCT, Double-blind | Tezepelumab, Tezepelumab |
| NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Non-Small Cell Lung Cancer (NSCLC) | P3 | Recruiting | 750 | RCT, Open-label | Sotorasib, Pembrolizumab |
| NCT07388498 A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout | Uncontrolled Gout | P3 | Recruiting | 270 | RCT, Double-blind | Pegloticase, Methotrexate |
| NCT07213674 A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | P3 | Recruiting | 750 | RCT, Open-label | Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel |
| NCT03836040 Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Migraine | P3 | Active | 457 | RCT, Double-blind | Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3 |
| NCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity | Sjogren's Syndrome | P3 | Active | 651 | RCT, Double-blind | Dazodalibep, Placebo |
| NCT05767047 A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis | Behçet's Disease, Juvenile Psoriatic Arthritis | P3 | Recruiting | 48 | Open-label | Apremilast |
| NCT07037433 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Atherosclerotic Cardiovascular Disease, Overweight | P3 | Recruiting | 12,800 | RCT, Double-blind | Maridebart Cafraglutide, Placebo |
| NCT07005128 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | P3 | Recruiting | 330 | RCT, Open-label | Tarlatamab, Durvalumab, Carboplatin, Etoposide |
| NCT03937154 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | Chemotherapy-induced Thrombocytopenia | P3 | Active | 145 | RCT, Double-blind | Romiplostim, Placebo |
| NCT03289299 Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | Smoldering Multiple Myeloma | P2 | Active | 87 | Open-label | Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone |
| NCT05848687 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Lymphoblastic Leukemia | P1P2 | Recruiting | 90 | Open-label | Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer, KRAS Activating Mutation | P1P2 | Active | 153 | Open-label | avutometinib and sotorasib, avutometinib and sotorasib and defactinib |
| NCT06054113 Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) | B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia | P2 | Active | 18 | Open-label | Blinatumomab |
| NCT06788938 Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | DLL3-expressing Tumors, Advanced Tumors | P2 | Recruiting | 29 | Open-label | Tarlatamab treatment |
| NCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Thyroid Eye Disease | P1P2 | Recruiting | 88 | RCT, Double-blind | AMG 732 |
| NCT00863460 Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients | Primary Central Nervous System Lymphoma | P2 | Active | 140 | RCT, Open-label | intensive chemotherapy and hematopoietic stem cell rescue, MTX based chemotherapy |
| NCT04430894 KRDI in Transplant-Eligible MM | Multiple Myeloma | P2 | Active | 50 | Single-blind | Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone |
| NCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | P1P2 | Active | 329 | Open-label | Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet |
| NCT07134088 A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | P1P2 | Recruiting | 104 | Open-label | Blinatumomab |
| NCT06502977 Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment | Extensive Stage Small Cell Lung Cancer | P2 | Active | 32 | Open-label | Tarlatamab |
| NCT06593522 A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | MTAP-deleted NSCLC | P2 | Recruiting | 200 | RCT, Open-label | AMG 193 |
| NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | Gastric Cancer, Gastroesophageal Junction Cancer | P1P2 | Active | 72 | Open-label | Bemarituzumab, CAPOX, SOX, Nivolumab |
| NCT05060016 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Relapsed/Refractory Small Cell Lung Cancer | P2 | Active | 222 | RCT, Open-label | Tarlatamab |
| NCT06745323 A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Small Cell Lung Cancer (SCLC) | P2 | Active | 252 | RCT, Open-label | Tarlatamab |
| NCT06570798 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | P2 | Recruiting | 220 | Open-label | Inebilizumab, Blinatumomab |
| NCT06660810 Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Soft Tissue Sarcoma, Sarcoma,Soft Tissue | P2 | Active | 2 | Open-label | Talimogene Laherparepvec |
| NCT04329325 Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive | P2 | Active | 17 | Open-label | Blinatumomab, dasatinib, dexamethasone, methotrexate |
| NCT07222579 Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) | CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL) | P2 | Recruiting | 78 | Open-label | Subcutaneous Blinatumomab |
| NCT04800367 Romosozumab/Denosumab Study for Premenopausal IOP | Premenopausal Idiopathic Osteoporosis | P2 | Active | 30 | Open-label | Romosozumab Prefilled Syringe [Evenity], Denosumab 60 MG/ML Prefilled Syringe [Prolia] |
| NCT07153796 A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | P2 | Recruiting | 60 | Open-label | Blinatumomab, Mini-CVD, MTX/ARA-C |
| NCT06312020 A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome | Sjogren's Syndrome | P2 | Active | 209 | RCT, Double-blind | HZN-1116, Placebo |
| NCT07037758 A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Extensive Stage Small Cell Lung Cancer | P1 | Recruiting | 380 | Open-label | Tarlatamab, AB248 |
| NCT02332850 Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Active | 83 | RCT, Open-label | Isatuximab, Carfilzomib, Dexamethasone |
| NCT06555796 Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | Prostate Cancer, High-risk Biochemical Recurrence | P1 | Active | 50 | Open-label | Xaluritamig |
| NCT06637371 A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Asthma | P1 | Recruiting | 124 | RCT, Double-blind | AMG 691, Placebo |
| NCT06807619 A Study of Sotorasib in People With Brain Tumors | Brain Tumor | P1 | Recruiting | 16 | Open-label | Sotorasib |
| NCT06613100 Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Prostate Cancer | P1 | Recruiting | 40 | Open-label | Xaluritamig, GnRH Antagonist |
| NCT06131398 A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Active | 77 | Open-label | AMG 355, Pembrolizumab |
| NCT06898957 Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer | P1 | Recruiting | 200 | Open-label | YL201, Tarlatamab, Atezolizumab, Durvalumab |
| NCT01959698 Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | P1 | Active | 29 | Open-label | Carboplatin, Carfilzomib, Etoposide, Ifosfamide, Rituximab |
| NCT07297979 Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | Ewing Sarcoma | P1 | Recruiting | 50 | Open-label | Xaluritamig |
| NCT06333951 AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Thoracic Tumors, Non-small Cell Lung Cancer | P1 | Recruiting | 500 | Open-label | AMG 193, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib |
| NCT07013578 TIDHI Mental Health in IBD Patients Study | Crohn Disease (CD), Ulcerative Colitis (UC) | N/A | Recruiting | 100 | RCT, Open-label | — |
| NCT01848028 PsoBest - The German Psoriasis Registry | Psoriasis, Psoriatic-arthritis | Recruiting | 3,500 | — | — | |
| NCT01277419 German Spondyloarthritis Inception Cohort | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA) | Recruiting | 1,000 | — | — | |
| NCT02009345 Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada | Familial Hypercholesterolemia, Lipid Disorder | Recruiting | 6,000 | — | — | |
| NCT04151342 CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) | Cancer, Malignancies Multiple | Recruiting | 5,500 | — | Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | |
| NCT06576050 WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise | Heart Failure, Obesity | Active | 21 | — | — | |
| NCT02208869 Russian Familial Hypercholesterolemia Registry | Familial Hypercholesterolemia | Recruiting | 1,000 | — | — | |
| NCT03851263 Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion | Coronary Artery Disease | P4 | Withdrawn | — | Open-label | Evolocumab |
| NCT00640393 Safety and Efficacy of Combining nbUVB to Etanercept in Patients | Psoriasis Vulgaris | P4 | Completed | 99 | RCT, Single-blind | Etanercept |
| NCT00967538 Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments | Psoriasis | P4 | Completed | 89 | Open-label | etanercept 50 mg |
| NCT03168529 Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit | Heart Failure | P4 | Terminated | 19 | RCT, Double-blind | Ivabradine, Placebo |
| NCT01313208 Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) | Rheumatoid Arthritis | P4 | Completed | 210 | RCT, Double-blind | etanercept, Placebo, DMARD Therapy |
| NCT00094341 Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes | Rheumatoid Arthritis | P4 | Completed | 215 | RCT, Open-label | Etanercept |
| NCT00443430 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis | Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis | P4 | Completed | 85 | RCT, Double-blind | methotrexate, methotrexate - etanercept - prednisolone arm |
| NCT00368901 STAAR-2 Clinical Study | Chronic Kidney Disease, Chronic Renal Insufficiency | P4 | Completed | 618 | Open-label | Darbepoetin alfa |
| NCT03774875 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life | Psoriasis | P4 | Completed | 277 | RCT, Double-blind | Apremilast, Placebo |
| NCT02246218 A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders | Urea Cycle Disorder | P4 | Completed | 27 | Open-label | RAVICTI |
| NCT02576652 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement | Osteoporosis | P4 | Completed | 6 | Open-label | — |
| NCT00037518 A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer | Hyperparathyroidism, Parathyroid Neoplasms | P4 | Completed | 46 | Open-label | AMG 073 |
| NCT03636373 Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout | Gout Attack | P4 | Terminated | 5 | RCT, Double-blind | Etanercept, Triamcinolone Acetonide |
| NCT00907478 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) | Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | P4 | Completed | 169 | Open-label | romiplostim |
| NCT00654368 CAMEO: Canadian Methotrexate and Etanercept Outcome Study | Rheumatoid Arthritis | P4 | Completed | 258 | RCT, Open-label | Etanercept, Methotrexate |
| NCT02749370 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast | Plaque Psoriasis | P4 | Completed | 80 | Open-label | Etanercept |
| NCT01250405 Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients | Chronic Kidney Disease | P4 | Completed | 23 | RCT, Double-blind | Cinacalcet, Placebo |
| NCT00117104 Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis | End Stage Renal Disease | P4 | Completed | — | Open-label | Aranesp® |
| NCT00121043 Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire | Rheumatoid Arthritis | P4 | Completed | — | RCT, Open-label | Kineret® (Anakinra) |
| NCT03335488 Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs) | Urea Cycle Disorder | P4 | Completed | 16 | RCT, Open-label | RAVICTI, NaPBA |
| NCT05135312 Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging | Psoriasis, Psoriatic Arthritis | P4 | Unknown | 10 | Open-label | Etanercept |
| NCT04265755 Biomarker and Genetic Predictors of Erenumab Treatment Response | Migraine | P4 | Completed | 1,406 | Open-label | Erenumab |
| NCT01053819 Can We Miss Pigmented Lesions in Psoriasis Patients? | Psoriasis, Melanoma | P4 | Completed | 6 | Open-label | etanercept |
| NCT03912337 Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine | Migraine | P4 | Terminated | 29 | RCT, Double-blind | Placebo, Erenumab |
| NCT03096288 Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity | Atherosclerotic Cardiovascular Disease | P4 | Completed | 259 | RCT, Double-blind | Evolocumab |
| NCT03971071 A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache | Migraine Headache | P4 | Completed | 620 | RCT, Double-blind | Erenumab 70 mg, Erenumab 140 mg, Placebo |
| NCT00259610 Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) | Rheumatoid Arthritis | P4 | Completed | 755 | RCT, Double-blind | methotrexate, sulfasalazine, hydroxychloroquine, etanercept |
| NCT00369733 STAAR-3 Clinical Study | Chronic Kidney Disease, Chronic Renal Insufficiency | P4 | Completed | 443 | Open-label | Darbepoetin alfa |
| NCT03783026 A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis | Psoriatic Arthritis | P4 | Completed | 123 | Open-label | Apremilast |
| NCT00127842 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) | Psoriatic Arthritis | P4 | Completed | 110 | Open-label | Etanercept |
| NCT03927144 Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | Episodic Migraine | P4 | Completed | 621 | RCT, Open-label | AMG334, Oral Prophylactic |
| NCT01901146 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer | Breast Cancer | P3 | Completed | 725 | RCT, Double-blind | ABP 980, Trastuzumab, Paclitaxel |
| NCT03029234 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P3 | Completed | 126 | Open-label | Dexamethasone, Carfilzomib |
| NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | P3 | Completed | 642 | RCT, Double-blind | Carboplatin, Paclitaxel, ABP 215, Bevacizumab |
| NCT00353119 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis | Palmoplantaris Pustulosis | P3 | Completed | 15 | RCT, Double-blind | Placebo comparator, Etanercept |
| NCT02126449 DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer | Fasting Mimicking Diet, Breast Cancer | P2P3 | Completed | 131 | RCT, Open-label | — |
| NCT00116181 Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis | Psoriasis | P3 | Completed | 30 | RCT, Open-label | Etanercept |
| NCT03433755 Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia | Primary Hypercholesterolemia, Mixed Dyslipidemia | P3 | Terminated | 259 | RCT, Double-blind | evolocumab, placebo |
| NCT00415532 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura | Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | P3 | Completed | 234 | RCT, Open-label | Medical Standard of Care for ITP, Romiplostim |
| NCT03287609 EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | Acute Coronary Syndrome | P3 | Completed | 308 | RCT, Double-blind | Evolocumab 140 mg/mL, Placebo |
| NCT01901185 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept | Rheumatoid Arthritis, Psoriatic Arthritis | P3 | Completed | 77 | Open-label | Etanercept / Autoinjector A |
| NCT01419717 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer | Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer | P3 | Completed | 129 | Open-label | Denosumab |
| NCT03638128 Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta | Osteogenesis Imperfecta (OI) | P3 | Terminated | 75 | Open-label | Denosumab, Alternative osteoporosis medications |
| NCT00117052 SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism | Secondary Hyperparathyroidism, End Stage Renal Disease | P3 | Completed | 673 | RCT, Open-label | cinacalcet |
| NCT00119613 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa | Small Cell Lung Cancer | P3 | Completed | 600 | RCT, Double-blind | placebo, darbepoetin alfa |
| NCT01099436 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients | Breast Cancer | P3 | Completed | 250 | RCT, Open-label | cyclophosphamide, docetaxel, doxorubicin hydrochloride, zoledronic acid |
| NCT00119587 Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects | Anemia | P3 | Completed | — | RCT, Double-blind | darbepoetin alfa |
| NCT02125344 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III | P3 | Completed | 961 | RCT, Open-label | non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel, Epirubicin, Cyclophosphamide, Pertuzumab, Trastuzumab, Ferric carboxymaltose |
| NCT03300609 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Colorectal Adenocarcinoma, RAS Wild Type | P3 | Terminated | 4 | RCT, Open-label | Panitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine |
| NCT03701763 Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 245 | RCT, Double-blind | Apremilast (CC-10004) |
| NCT00339183 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | Metastatic Colorectal Cancer | P3 | Completed | 1,186 | RCT, Open-label | Panitumumab, FOLFIRI |
| NCT00356356 16.0040 Ankylosing Spondylitis Study | Ankylosing Spondylitis | P3 | Completed | 257 | Open-label | Etanercept |
| NCT01412957 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P3 | Completed | 377 | RCT, Open-label | Panitumumab |
| NCT00523341 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis | Osteopenia, Osteoporosis | P3 | Completed | 4,550 | Open-label | Denosumab |
| NCT04175613 A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 160 | Open-label | Apremilast |
| NCT03570697 Imaging of Coronary Plaques in Participants Treated With Evolocumab | Coronary Artery Disease (CAD) | P3 | Completed | 164 | RCT, Double-blind | Evolocumab, Placebo, Statin therapy |
| NCT00041665 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy | Stomatitis | P3 | Completed | — | RCT, Double-blind | Recombinant Human Keratinocyte Growth Factor |
| NCT00089674 AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer | Prostate Cancer | P3 | Completed | 1,468 | RCT, Double-blind | AMG 162, Placebo |
| NCT01444417 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients | Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | P3 | Completed | 62 | RCT, Double-blind | Romiplostim, Placebo |
| NCT01270347 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients | Cystic Fibrosis | P3 | Completed | 282 | RCT, Open-label | MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution) |
| NCT02341417 Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis | Secondary Hyperparathyroidism, Chronic Kidney Disease | P3 | Completed | 28 | Open-label | Cinacalcet |
| NCT00358215 RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial | Heart Failure, Anemia | P3 | Completed | 2,278 | RCT, Double-blind | Darbepoetin alfa, Placebo |
| NCT03689946 Effect of Evolocumab on Coronary Atherosclerosis | Cardiovascular Disease, Hyperlipidemia | P3 | Completed | 55 | Open-label | Evolocumab, Omnipaque, Metoprolol, Nitroglycerin |
| NCT03461211 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study | Thyroid Eye Disease | P3 | Completed | 51 | Open-label | Teprotumumab |
| NCT01733316 Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis | Cystinosis | P3 | Completed | 41 | Open-label | RP103, Cystagon® |
| NCT00169104 Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | Metastatic Breast Cancer | P2P3 | Terminated | 23 | RCT, Double-blind | G-CSF, trastuzumab, vinorelbine, G-CSF, saline placebo |
| NCT00111449 Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis | Psoriasis | P3 | Completed | 600 | RCT, Double-blind | Etanercept |
| NCT07223190 A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | P3 | Not Yet Recruiting | 560 | RCT, Open-label | Blinatumomab, Blinatumomab, HyperCVAD |
| NCT00785421 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer | Pancreatic Cancer | P2P3 | Completed | 312 | RCT, Open-label | enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy |
| NCT00091793 Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis | Postmenopausal Osteoporosis | P3 | Completed | 332 | RCT, Double-blind | AMG 162, Placebo |
| NCT05724199 A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | P3 | Completed | 746 | RCT, Double-blind | Rocatinlimab |
| NCT01984424 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 | Hyperlipidemia | P3 | Completed | 511 | RCT, Double-blind | Atorvastatin, Placebo to Atorvastatin, Ezetimibe, Evolocumab |
| NCT02376790 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis | Psoriatic Arthritis | P3 | Completed | 851 | RCT, Double-blind | Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate |
| NCT03347279 Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma | Asthma | P3 | Completed | 1,061 | RCT, Double-blind | Experimental: Tezepelumab |
| NCT00117091 Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Completed | — | Open-label | Anakinra (Kineret®) |
| NCT01197378 Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) | Cystinosis | P3 | Completed | 60 | Open-label | Cysteamine Bitartrate Delayed-release Capsules |
| NCT00094484 Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis | Kidney Disease, Chronic Kidney Disease | P3 | Completed | 400 | RCT, Double-blind | Cinacalcet HCl |
| NCT01631214 Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis | Postmenopausal Women With Osteoporosis | P3 | Completed | 4,093 | RCT, Double-blind | Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate |
| NCT00450216 Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment | Ulcer | P3 | Completed | 906 | RCT, Double-blind | Ibuprofen/famotidine, Ibuprofen |
| NCT01879319 Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen | Primary Hypercholesterolemia, Mixed Dyslipidemia | P3 | Completed | 164 | RCT, Open-label | Evolocumab AMD, Evolocumab AI/pen |
| NCT00116688 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | P3 | Completed | 313 | RCT, Open-label | Romiplostim |
| NCT00450658 Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers | Peptic Ulcer | P3 | Completed | 627 | RCT, Double-blind | HZT-501, Ibuprofen |
| NCT03859427 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | P3 | Completed | 454 | RCT, Open-label | Carfilzomib, Carfilzomib, Lenalidomide, Dexamethasone |
| NCT00527267 Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects | Hyperparathyroidism | P3 | Completed | 320 | RCT, Double-blind | Placebo, AMG 073 |
| NCT01568866 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients | Multiple Myeloma | P3 | Completed | 929 | RCT, Open-label | Carfilzomib, Bortezomib, Dexamethasone |
| NCT01281254 AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | Fallopian Tube Cancer, Ovarian Cancer | P3 | Terminated | 223 | RCT, Double-blind | AMG386 plus PLD, Placebo plus PLD |
| NCT03811418 A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | Advanced Breast Cancer, HER2-positive Breast Cancer | P3 | Withdrawn | — | RCT, Open-label | Trastuzumab, Pertuzumab, Vinorelbine, Docetaxel |
| NCT05398263 Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma | Asthma | P3 | Terminated | 125 | RCT, Double-blind | Tezepelumab |
| NCT00115167 A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study | Anemia, Cancer | P3 | Completed | 371 | RCT, Double-blind | Placebo, Darbepoetin alfa |
| NCT02585895 Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment | Hypercholesterolemia | P3 | Completed | 39 | RCT, Open-label | Evolocumab |
| NCT01302392 A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P3 | Completed | 315 | RCT, Open-label | Carfilzomib, Best Supportive Care |
| NCT01624142 Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders | Severe Familial Hypercholesterolemia | P2P3 | Completed | 300 | Open-label | Evolocumab |
| NCT03930186 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy | Plaque Psoriasis | P3 | Completed | 152 | Open-label | Apremilast, Topical Therapy |
| NCT00115765 PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | Colorectal Cancer | P3 | Completed | 1,053 | RCT, Open-label | Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy, Bevacizumab |
| NCT00925600 Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | Cancer, Cataract | P3 | Completed | 769 | RCT, Double-blind | Denosumab, Placebo |
| NCT04851964 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis | Chronic Rhinosinusitis With Nasal Polyps | P3 | Completed | 416 | RCT, Double-blind | Experimental: Tezepelumab, Mometasone furoate or equivalent intranasal corticosteroid |
| NCT00557817 Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) | Hematological Malignancies | P2P3 | Completed | 125 | RCT, Open-label | Darbepoetin alpha (Aranesp), Iron saccharate (Venofer) |
| NCT02797080 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | Friedreich's Ataxia | P3 | Completed | 38 | Open-label | interferon γ-1b |
| NCT00117910 Treatment for Elderly Patients With High Risk Breast Cancer | Breast Cancer | P3 | Completed | — | RCT, Open-label | pegfilgrastim |
| NCT03406078 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma | Asthma | P3 | Completed | 150 | RCT, Double-blind | Tezepelumab |
| NCT01180634 MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis | Cystic Fibrosis | P3 | Completed | 330 | RCT, Double-blind | Aeroquin, Placebo |
| NCT02791516 A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis | Postmenopausal Osteoporosis | P3 | Completed | 67 | RCT, Double-blind | Romosozumab, Placebo |
| NCT00093015 Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) | Kidney Disease, Diabetes Mellitus | P3 | Completed | 4,038 | RCT, Double-blind | Placebo, darbepoetin alfa |
| NCT03080935 Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries | Dyslipidemia | P3 | Terminated | 1,600 | Open-label | Evolocumab |
| NCT00984282 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | Thyroid Neoplasms | P3 | Completed | 417 | RCT, Double-blind | Sorafenib (Nexavar, BAY43-9006), Placebo |
| NCT00111007 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | Melanoma | P3 | Completed | 270 | RCT, Double-blind | Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo |
| NCT00544232 Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | Breast Cancer | P3 | Completed | 720 | RCT, Open-label | Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa, Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa |
| NCT02986139 Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis | Arthritis, Rheumatoid; Arthritis, Psoriatic | P3 | Completed | 111 | RCT, Double-blind | Commercial Formulation Etanercept, New Formulation Etanercept |
| NCT00345839 E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events | Secondary Hyperparathyroidism, Chronic Kidney Disease | P3 | Completed | 3,883 | RCT, Double-blind | Cinacalcet, Placebo |
| NCT01854918 Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia | Hyperlipidemia and Mixed Dyslipidemia | P3 | Completed | 3,681 | RCT, Open-label | Evolocumab, Standard of Care |
| NCT00364013 PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | Metastatic Colorectal Cancer | P3 | Completed | 1,183 | RCT, Open-label | Panitumumab, FOLFOX regimen |
| NCT00436748 Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease | Anemia, Chronic Kidney Disease | P3 | Terminated | 116 | RCT, Double-blind | Darbepoetin Alfa, Placebo |
| NCT01764633 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk | Dyslipidemia | P3 | Completed | 27,564 | RCT, Double-blind | Evolocumab, Placebo |
| NCT00838201 Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | Cancer, Carcinoma | P3 | Completed | 384 | Open-label | Denosumab |
| NCT02994927 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis | ANCA-Associated Vasculitis | P3 | Completed | 331 | RCT, Double-blind | Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine |
| NCT02393859 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | Leukemia, Acute Lymphoblastic | P3 | Completed | 111 | RCT, Open-label | Blinatumomab, Dexamethasone, Vincrisitne, Daunorubicin, Methotrexate, Ifosfamide, PEG-asparaginase, Erwinia-asparaginase |
| NCT00534456 An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial | Anemia, Cardiovascular Disease | P3 | Terminated | 12 | RCT, Double-blind | Placebo, Darbepoetin alfa |
| NCT00377819 Study of Transitioning From Alendronate to Denosumab | Postmenopausal Osteoporosis | P3 | Completed | 504 | RCT, Double-blind | alendronate, Denosumab (AMG 162) |
| NCT00984815 Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment | Osteoarthritis, Rheumatoid Arthritis | P3 | Completed | 86 | Open-label | HZT-501 |
| NCT00110903 Treatment for Subjects With Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P3 | Completed | — | Open-label | Etanercept Liquid |
| NCT02729025 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) | Subjects With Hyperlipidemia, Dyslipidemia | P3 | Completed | 129 | RCT, Double-blind | Evolocumab, Placebo |
| NCT00286091 Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer | Hormone Refractory Prostate Cancer | P3 | Completed | 1,435 | RCT, Double-blind | Denosumab, Placebo |
| NCT00556374 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | Breast Cancer | P3 | Completed | 3,420 | RCT, Double-blind | Placebo, Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid |
| NCT02138838 Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis | Chronic Kidney Disease, Secondary Hyperparathyroidism | P3 | Terminated | 55 | RCT, Open-label | Cinacalcet HCl |
| NCT03780959 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA) | Juvenile Rheumatoid Arthritis | P2P3 | Completed | 69 | RCT, Double-blind | Etanercept, Placebo |
| NCT02373813 Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission | Rheumatoid Arthritis | P3 | Completed | 371 | RCT, Double-blind | etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate |
| NCT01362140 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | MDS | P3 | Completed | 147 | RCT, Double-blind | Darbepoetin alfa, Placebo |
| NCT03476239 Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | P3 | Completed | 121 | Open-label | Blinatumomab, Dexamthasone |
| NCT01970475 Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis | Arthritis, Rheumatoid | P3 | Completed | 526 | RCT, Double-blind | ABP 501, Adalimumab |
| NCT01763866 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 | Hyperlipidemia | P3 | Completed | 2,067 | RCT, Double-blind | Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin |
| NCT01277510 Pediatric Chronic Kidney Disease Safety and Efficacy | Chronic Kidney Disease, Hyperparathyroidism | P3 | Terminated | 43 | RCT, Double-blind | cinacalcet capsule, placebo, Standard of Care |
| NCT01583374 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis | Ankylosing Spondyloarthritis | P3 | Completed | 490 | RCT, Double-blind | Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo |
| NCT01818752 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | Multiple Myeloma | P3 | Completed | 955 | RCT, Open-label | Carfilzomib, Bortezomib, Melphalan, Prednisone |
| NCT01313221 Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis | Psoriasis | P3 | Completed | 310 | RCT, Single-blind | etanercept, Topical agents |
| NCT01763918 Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 | Hyperlipidemia | P3 | Completed | 331 | RCT, Double-blind | Evolocumab, Placebo |
| NCT00975000 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients | Chronic Allograft Nephropathy, Chronic Kidney Disease | P3 | Completed | 114 | RCT, Double-blind | Cinacalcet, Placebo |
| NCT00657644 Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction | Erectile Dysfunction | P3 | Completed | 130 | Open-label | Levitra (Vardenafil, BAY38-9456) |
| NCT00911170 PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study | Cancer, Colon Cancer | P3 | Completed | 847 | RCT, Double-blind | Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy |
| NCT02593773 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study | Friedreich's Ataxia | P3 | Completed | 86 | Open-label | Interferon γ-1b |
| NCT00111111 An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis | Psoriasis | P3 | Completed | — | RCT, Open-label | Etanercept |
| NCT00101582 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | Mucositis, Solid Tumors | P3 | Completed | 188 | RCT, Double-blind | Placebo, palifermin, cisplatin chemotherapy |
| NCT02456740 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention | Migraine | P3 | Completed | 955 | RCT, Double-blind | Erenumab, Placebo |
| NCT04169347 FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Colorectal Cancer Metastatic | P2 | Unknown | 27 | Open-label | Oxaliplatin |
| NCT00346099 Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum | Rectal Cancer, Neoplasm Metastasis | P2 | Withdrawn | — | Open-label | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation |
| NCT05180422 A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | Non Small Cell Lung Cancer | P1P2 | Withdrawn | — | Open-label | AMG 510, MVASI |
| NCT00591851 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | Breast Cancer | P2 | Completed | 70 | Open-label | AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) |
| NCT06068153 AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC | Metastatic Non Small Cell Lung Cancer, KRAS G12C | P2 | Withdrawn | — | Open-label | Sotorasib, Lenvatinib |
| NCT00632541 A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Terminated | 18 | Open-label | Sorafenib, Bevacizumab |
| NCT07178912 Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | Phase II Clinical Trial, Blinatumomab | P2 | Not Yet Recruiting | 60 | Open-label | Blinatumomab, olverembatinib |
| NCT00193479 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | P2 | Completed | 51 | Open-label | Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab |
| NCT00940316 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | P2 | Completed | 28 | RCT, Open-label | panitumumab, erlotinib hydrochloride, irinotecan hydrochloride |
| NCT00400764 A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas | Non-Hodgkin's Lymphoma | P1P2 | Terminated | 72 | RCT, Open-label | Dulanermin, Rituximab |
| NCT04448834 Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | B-cell Acute Lymphoblastic Leukemia | P2 | Withdrawn | — | Open-label | Blinatumomab |
| NCT03301467 Controlled Trial Evaluating Avacopan in C3 Glomerulopathy | C3 Glomerulopathy (C3G) | P2 | Completed | 57 | RCT, Double-blind | Avacopan, Avacopan Matching Placebo |
| NCT04338581 Evaluation of AMG 714 for Vitiligo | Vitiligo | P2 | Completed | 60 | RCT, Double-blind | AMG 714, Placebo |
| NCT01464034 A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 136 | Open-label | Carfilzomib, Pomalidomide, Dexamethasone |
| NCT00508625 A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | Non-Small Cell Lung Cancer | P2 | Completed | 213 | RCT, Open-label | AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin, Paclitaxel |
| NCT00293202 Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients | End Stage Renal Disease | P2 | Terminated | 10 | RCT, Double-blind | Etanercept, Placebo |
| NCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Non-Small Cell Lung Cancer | P2 | Completed | 47 | Open-label | RMC-4630, Sotorasib |
| NCT03160079 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | B-Cell Acute Lymphoblastic Leukemia, Adult | P1P2 | Completed | 16 | Open-label | blinatumomab, pembrolizumab |
| NCT04129164 A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | Sjögren's Syndrome | P2 | Completed | 183 | RCT, Double-blind | VIB4920, Placebo |
| NCT00597909 Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy | Hepatic Encephalopathy | P2 | Terminated | 1 | RCT, Double-blind | sodium phenylacetate and sodium benzoate injection 10% / 10%, sodium phenylacetate and sodium benzoate injection 10% / 10%, placebo solution (10% dextrose) |
| NCT07301424 Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | P2 | Not Yet Recruiting | 80 | Open-label | Treatment with blinatumomab given subcutaneously. |
| NCT03795558 A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients | End Stage Renal Disease | P2 | Completed | 37 | Open-label | Etelcalcetide |
| NCT02453191 TVEC and Preop Radiation for Sarcoma (4 ml Dose) | Soft Tissue Sarcoma | P1P2 | Completed | 30 | Open-label | Talimogene Laherparepvec |
| NCT00841789 A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease | Mucocutaneous Lymph Node Syndrome, Kawasaki Disease | P2 | Completed | 205 | RCT, Double-blind | Etanercept, Placebo |
| NCT00526929 Fixed Dose NESP Study in Subjects With CRI | Pre-Dialysis | P2 | Completed | 75 | Open-label | darbepoetin alfa |
| NCT00037700 Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | — | RCT, Double-blind | anakinra, pegsunercept |
| NCT00079612 Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | Carcinoma, Renal Cell | P2 | Completed | 501 | RCT, Double-blind | Sorafenib (Nexavar, BAY43-9006), Placebo |
| NCT00095264 A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome | Myelodysplastic Syndromes | P2 | Completed | 209 | Open-label | Darbepoetin Alfa |
| NCT00000626 Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | HIV Infections, Hodgkin's Disease | P2 | Completed | 27 | — | Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride |
| NCT00639717 Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant | Graft Versus Host Disease | P2 | Completed | 48 | Open-label | tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen |
| NCT02087943 Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic Dermatitis | P2 | Completed | 191 | RCT, Double-blind | Apremilast, Apremilast, Placebo, Placebo |
| NCT01466179 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | P2 | Completed | 225 | Open-label | Blinatumomab |
| NCT01379807 Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P2 | Unknown | 55 | Open-label | panitumumab + docetaxel + cisplatino |
| NCT04330430 Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease | Melanoma Stage III, Melanoma Stage IV | P2 | Completed | 24 | Open-label | T-VEC |
| NCT03137537 Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. | Lymphoma, Autonomic Imbalance | P2 | Terminated | 23 | RCT, Double-blind | Ivabradine, Placebo Oral Tablet |
| NCT02429882 Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis | Axial Spondyloarthritis | P2 | Withdrawn | — | RCT, Double-blind | Brodalumab 210 mg, Placebo |
| NCT00594620 Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy | Prostate Cancer | P2 | Terminated | 11 | RCT, Double-blind | Placebo |
| NCT03809663 A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 251 | RCT, Double-blind | Tezepelumab |
| NCT02464891 Complement Inhibition in aHUS Dialysis Patients | Atypical Hemolytic Uremic Syndrome | P2 | Terminated | 6 | Open-label | CCX168 |
| NCT02412306 Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia | P1P2 | Completed | 66 | Open-label | Blinatumomab |
| NCT02833610 A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | Multiple Myeloma | P2 | Completed | 55 | Open-label | Denosumab Q4W |
| NCT04231682 A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients. | Osteoporosis | P2 | Withdrawn | — | RCT, Double-blind | Denosumab Injection, Placebos |
| NCT01234324 ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction | Stomach Neoplasms, Gastroesophageal Junction Neoplasms | P2 | Completed | 171 | RCT, Open-label | Epirubicin, Cisplatin, Capecitabine, Panitumumab, Epirubicin, Cisplatin, Capecitabine |
| NCT01987232 Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | Extensive-Stage Small-Cell Lung Cancer | P1P2 | Completed | 32 | Open-label | Carfilzomib, Carboplatin, Etoposide |
| NCT00113958 Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels | End Stage Renal Disease | P2 | Completed | — | Open-label | Cinacalcet |
| NCT06333678 A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | P2 | Completed | 10 | RCT, Open-label | Durvalumab, Sotorasib |
| NCT02289417 Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis | Ulcerative Colitis | P2 | Completed | 170 | RCT, Double-blind | Apremilast, Placebo |
| NCT01150890 Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease | Crohn's Disease | P2 | Terminated | 130 | RCT, Double-blind | Brodalumab, Placebo |
| NCT04478123 Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer | Multiple Myeloma, Hodgkin Lymphoma | P2 | Completed | 62 | Open-label | Romiplostim |
| NCT01351623 Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Completed | 44 | Open-label | Carfilzomib |
| NCT04039113 Tezepelumab COPD Exacerbation Study | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Completed | 337 | RCT, Double-blind | Tezepelumab |
| NCT00321711 Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents | MDS, Myelodysplastic Syndromes | P2 | Completed | 69 | RCT, Double-blind | Placebo, AMG 531 (Romiplostim), Azacitidine, Decitabine |
| NCT02227914 Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | P1P2 | Withdrawn | — | RCT, Open-label | Oprozomib, Sorafenib |
| NCT00936650 A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT) | Hyperparathyroidism, Primary | P2 | Completed | 78 | RCT, Double-blind | placebo, cinacalcet |
| NCT00661141 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | P2 | Completed | 32 | RCT, Double-blind | Antizol, Placebo |
| NCT00050674 Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer | P2 | Completed | 40 | Open-label | Filgrastim-SD/01 |
| NCT00756444 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of Head and Neck | P2 | Completed | 67 | RCT, Open-label | Panitumumab, Cisplatin, 5FU |
| NCT03238781 Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention | Chronic Migraine or Episodic Migraine | P2 | Completed | 343 | RCT, Double-blind | Placebo, AMG 301 |
| NCT01568216 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms | Schizophrenia | P2 | Terminated | 121 | RCT, Double-blind | AMG 747, Placebo |
| NCT04270760 Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study | Cardiovascular Disease | P2 | Completed | 281 | RCT, Double-blind | Olpasiran, Placebo |
| NCT01907308 Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Urothelial Carcinoma | P2 | Withdrawn | — | Open-label | AMG 386, Docetaxel |
| NCT01285310 Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 237 | RCT, Double-blind | Apremilast 30 mg, Apremilast 20 mg, Placebo |
| NCT00035620 Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy | Sarcoma, Neutropenia | P2 | Completed | 44 | RCT, Open-label | pegfilgrastim, filgrastim |
| NCT01701076 Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P2 | Completed | 50 | Open-label | Bendamustine |
| NCT00411450 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment | Colon Cancer, Colorectal Cancer | P2 | Completed | 116 | Open-label | Panitumumab, FOLFIRI |
| NCT01902290 Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility | Asthma | P2 | Terminated | 421 | RCT, Double-blind | Placebo, Brodalumab |
| NCT00117455 A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | P2 | Completed | — | RCT, Double-blind | pegfilgrastim, filgrastim |
| NCT00049985 Heart Failure and Anemia | Heart Failure, Anemia | P2 | Completed | 300 | RCT, Double-blind | Darbepoetin Alfa |
| NCT02779855 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | Breast Cancer, Ductal Carcinoma | P1P2 | Completed | 50 | Open-label | Talimogene laherparepvec, Paclitaxel |
| NCT01143038 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim | Idiopathic Thrombocytopenic Purpura | P2 | Completed | 75 | Open-label | Romiplostim |
| NCT02000427 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory Philadelphia Positive B-precursor ALL | P2 | Completed | 45 | Open-label | Blinatumomab |
| NCT00120705 Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy | Neoplasms, Anemia | P2 | Completed | 204 | RCT, Open-label | darbepoetin alfa |
| NCT03298412 Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) | High-risk Diffuse Large B-cell Lymphoma | P2 | Terminated | 10 | Open-label | Blinatumomab |
| NCT00751894 Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) | Solid Malignancies | P2 | Unknown | 30 | Open-label | Pegfilgrastim (Neulasta, Amgen) |
| NCT00189488 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | Graft Versus Host Disease, Hematologic Malignancies | P2 | Completed | 155 | RCT, Double-blind | Palifermin, Placebo, Methotrexate |
| NCT05591222 Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus | Discoid Lupus Erythematosus | P2 | Terminated | 72 | RCT, Double-blind | Placebo, Daxdilimab |
| NCT00231582 High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II | Testicular Neoplasms | P2 | Completed | 50 | Open-label | epirubicin, paclitaxel, etoposide, ifosfamide, carboplatin |
| NCT01172717 Study of Panitumumab in the Treatment of Carcinoid Syndrome | Carcinoid Syndrome | P2 | Withdrawn | — | Open-label | Panitumumab |
| NCT01017653 Panitumumab and Irinotecan for Malignant Gliomas | Malignant Glioma of Brain | P2 | Terminated | 16 | Open-label | Irinotecan, Panitumumab |
| NCT00500760 Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer | Head and Neck Cancer, Squamous Cell Carcinoma | P2 | Completed | 153 | RCT, Open-label | Cisplatin, Panitumumab |
| NCT02215200 ATG-GCSF in New Onset Type 1 Diabetes | Diabetes Mellitus, Type 1 | P2 | Completed | 89 | RCT, Double-blind | Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF) |
| NCT03512353 A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | Relapsed or Refractory Multiple Myeloma | P2 | Terminated | 7 | Open-label | Dexamethasone, Carfilzomib |
| NCT00005960 Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | Pain, Prostate Cancer | P2 | Unknown | — | — | filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride |
| NCT01568229 20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165) | Schizophrenia | P2 | Terminated | 111 | RCT, Double-blind | AMG 747, Placebo |
| NCT01128387 Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer | Cancer | P1P2 | Terminated | 11 | Open-label | Panitumumab |
| NCT00865709 Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects | Metastatic Colorectal Cancer | P2 | Completed | 198 | RCT, Double-blind | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) |
| NCT00038298 A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate | Rheumatoid Arthritis | P2 | Completed | 53 | RCT, Double-blind | Placebo, AMG 719, AGM 719, AMG 719, placebo to AMG 719 |
| NCT04987307 Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2 | Terminated | 221 | RCT, Double-blind | Efavaleukin alfa, Placebo |
| NCT01792102 Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | Multiple Myeloma | P1P2 | Unknown | 38 | Open-label | Carfilzomib and Dexamethasone |
| NCT01016795 Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma | Malignant Lymphoma | P2 | Terminated | 32 | RCT, Double-blind | r-metHuSCF and Filgrastim, r-metHuSCF and Filgrastim, Chemotherapy plus Filgrastim |
| NCT00401544 Darbepoetin Alfa With or Without Intravenous (IV) Iron | Anemia, Non-Myeloid Malignancies | P2 | Completed | 243 | RCT, Double-blind | darbepoetin alfa, IV iron dextran |
| NCT04082442 Evolocumab in Patients With Acute MI | Acute Coronary Syndrome | P2 | Completed | 100 | RCT, Double-blind | Evolocumab, Placebos |
| NCT00757172 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | P2 | Completed | 70 | Open-label | panitumumab, cisplatin, docetaxel |
| NCT00585650 Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet | Psoriasis | P1P2 | Completed | 20 | RCT, Double-blind | Etanercept |
| NCT01313884 Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | Bone Cancer, Ewing's Sarcoma | P2 | Terminated | 3 | Open-label | Irinotecan, Vincristine, Temozolomide, Doxorubicin, Cytoxan, Pegfilgrastim |
| NCT04785547 ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | ALL, Childhood, Minimal Residual Disease | P2 | Terminated | 3 | Open-label | Blinatumomab |
| NCT01328171 FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | Metastatic Colorectal Cancer | P2 | Completed | 93 | RCT, Open-label | FOLFOXIRI + Panitumumab, FOLFOXIRI |
| NCT01375764 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects | Hyperlipidemia | P2 | Completed | 160 | RCT, Double-blind | Evolocumab, Ezetimibe |
| NCT03620019 Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | Melanoma Stage Iii, Melanoma Stage Iv | P2 | Completed | 25 | Open-label | Denosumab, Pembrolizumab, Nivolumab |
| NCT00360867 An Open Label Treatment Extension Study of AMG 706 | Solid Tumors | P2 | Terminated | 94 | Open-label | AMG 706 |
| NCT01175733 Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer | Pancreatic Cancer | P1P2 | Completed | 18 | Open-label | Panitumumab |
| NCT03852472 Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) | Hidradenitis Suppurativa, Acne Inversa | P2 | Completed | 435 | RCT, Double-blind | Avacopan |
| NCT00884312 A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | Multiple Myeloma, Solid Tumors | P2 | Completed | 101 | Open-label | Carfilzomib |
| NCT00936988 A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism | Hyperparathyroidism, Primary | P2 | Completed | 45 | Open-label | cinacalcet |
| NCT01207388 Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | B-cell Acute Lymphoblastic Leukemia | P2 | Completed | 116 | Open-label | Blinatumomab |
| NCT00095277 Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer | Anemia | P2 | Completed | 220 | RCT, Double-blind | Darbepoetin Alfa |
| NCT00283439 A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma | P1P2 | Completed | 39 | Open-label | AMG 531 |
| NCT03280667 Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer | P2 | Unknown | 59 | Open-label | Pembrolizumab plus denosumab |
| NCT00511238 Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P2 | Completed | 312 | Open-label | carfilzomib, carfilzomib |
| NCT00037648 Juvenile Rheumatoid Arthritis | Juvenile Chronic Arthritis | P2 | Completed | 86 | RCT, Double-blind | Anakinra, Placebo |
| NCT00661921 A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus | P2 | Withdrawn | — | RCT, Double-blind | AMG 108, Placebo |
| NCT01290263 Amgen 386 for Recurrent Glioblastoma | Glioblastoma Multiforme | P1P2 | Completed | 48 | Open-label | Amgen 386, Bevacizumab |
| NCT00682383 Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | Unresectable Locally Advanced NSCLC | P2 | Completed | 26 | Open-label | Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta |
| NCT02597062 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | Multiple Myeloma | P2 | Completed | 76 | Open-label | Carfilzomib, Cyclophosphamide, Dexamethasone |
| NCT01288339 Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Completed | 78 | Open-label | Panitumumab + FOLFOX (DP), Panitumumab + FOLFOX (no-DP) |
| NCT00113945 Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD) | End Stage Renal Disease | P2 | Completed | 360 | Open-label | Cinacalcet |
| NCT03070002 Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells | Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count | P2 | Terminated | 1 | Open-label | Denosumab |
| NCT00001059 Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | Sarcoma, Kaposi, HIV Infections | P2 | Completed | 120 | — | Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate, Vincristine sulfate |
| NCT04556084 Blinatumomab Bridging Therapy for BALL | B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | P2 | Terminated | 2 | Open-label | Blinatumomab |
| NCT04427306 Neoadjuvant T-VEC in High Risk Early Melanoma | Melanoma | P2 | SUSPENDED | 6 | Open-label | T-Vec |
| NCT00356681 A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | Breast Neoplasms, Breast Tumors | P2 | Terminated | 282 | RCT, Double-blind | AMG 706 placebo, Bevacizumab, AMG 706, Paclitaxel |
| NCT00730392 Etanercept in New Onset Type 1 Diabetes | Type 1 Diabetes | P1P2 | Completed | 18 | RCT, Double-blind | Etanercept, Placebo |
| NCT00067639 Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma | Multiple Myeloma | P2 | Completed | 50 | Open-label | Pegfilgrastim (Neulasta) |
| NCT02335268 Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia | Myelodysplastic Syndromes | P2 | Completed | 77 | Open-label | N-Plate / romiplostim |
| NCT01194869 Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer | Breast Cancer | P2 | Terminated | 25 | Open-label | Sorafenib, Cisplatin, Paclitaxel |
| NCT01296035 Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | Ovarian Cancer, Fallopian Tube Cancer | P2 | Terminated | 8 | Open-label | Panitumumab |
| NCT01349088 Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Breast Cancer, Metastatic Breast Cancer | P1P2 | Withdrawn | — | Open-label | Ixabepilone, Capecitabine, Motesanib |
| NCT01199289 A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma | Asthma | P2 | Completed | 315 | RCT, Double-blind | AMG 827, Placebo |
| NCT00113789 Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | Ovarian Cancer | P2 | Completed | 21 | RCT, Double-blind | — |
| NCT01696396 Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease | Crohn's Disease | P2 | Completed | 254 | RCT, Double-blind | Abrilumab, Placebo |
| NCT03688074 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) | Asthma, Bronchial Diseases | P2 | Completed | 116 | RCT, Double-blind | Tezepelumab |
| NCT00770848 AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | Cancer, Castrate-Resistant Prostate Cancer | P1P2 | Completed | 162 | RCT, Double-blind | AMG 102, AMG 102, Mitoxantrone, Placebo, Prednisone |
| NCT00094835 Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Lung Cancer, Non-Small Cell Lung Cancer | P1P2 | Completed | 51 | Open-label | Panitumumab, Motesanib diphosphate, Paclitaxel, Carboplatin |
| NCT02983097 Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°) | P1P2 | Terminated | 34 | Open-label | Rituximab, Cisplatin, Carboplatin, Dexamethasone, Cytarabine, Lenalidomide, PegFilgrastim |
| NCT02420587 AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Prostate Cancer | P2 | Withdrawn | — | Open-label | AMG 208 |
| NCT00083616 Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy | Colorectal Cancer, Metastatic Cancer | P2 | Completed | 185 | Open-label | Panitumumab |
| NCT00885885 Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases | Colorectal Cancer | P2 | Completed | 80 | RCT, Open-label | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI |
| NCT00117143 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura | P1P2 | Completed | 16 | Open-label | Romiplostim |
| NCT00306189 A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects | Osteoporosis | P2 | Completed | 212 | RCT, Double-blind | 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo |
| NCT03656666 The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus | Lichen Planus of Vulva, Female Genital Disease | P2 | Unknown | 42 | RCT, Double-blind | Apremilast, Placebo |
| NCT04057937 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis | Palmoplantaris Pustulosis | P2 | Completed | 90 | RCT, Double-blind | Apremilast, Placebo |
| NCT00540384 Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy | Anemia, Solid Tumors | P1P2 | Completed | 405 | RCT, Double-blind | Placebo, Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) |
| NCT03773107 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 12 | Open-label | Carfilzomib, Ruxolitinib, Dexamethasone |
| NCT01024387 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | Neuroendocrine Tumor, Carcinoid Tumor | P2 | Completed | 60 | Open-label | AMG 479 |
| NCT01325194 CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis | Primary Disease | P2 | Completed | 143 | Open-label | liposomal cytarabine |
| NCT03605199 Denosumab in Subjects With Giant Cell Rich Tumors of Bone | Aneurysmal Bone Cysts, Giant Cell Granuloma | P2 | Unknown | 60 | Open-label | Denosumab |
| NCT03155100 Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines | Multiple Myeloma in Relapse | P2 | Completed | 15 | Open-label | Carfilzomib for Inj 60 milligram (MG), Elotuzumab 400 MG, Dexamethasone |
| NCT01470196 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | Waldenstrom's Macroglobulinemia | P2 | Completed | 31 | Open-label | Dexamethasone, Carfilzomib, Rituximab |
| NCT00293813 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density | Postmenopausal Osteoporosis | P2 | Completed | 247 | RCT, Double-blind | Alendronate, Denosumab, Placebo |
| NCT03410056 Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis RA | P1P2 | Terminated | 36 | RCT, Double-blind | Efavaleukin alfa, Placebo |
| NCT00101413 BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) | Cancer, Carcinoma, Non-Small Cell Lung | P2 | Completed | 52 | Open-label | Sorafenib (Nexavar, BAY43-9006) |
| NCT00094861 Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Dysphagia, Non-Small Cell Lung Cancer | P2 | Completed | 100 | RCT, Double-blind | Palifermin, Placebo, Paclitaxel, Carboplatin |
| NCT00866359 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease | Behcet Syndrome | P2 | Completed | 111 | RCT, Double-blind | Apremilast (CC-10004), Placebo |
| NCT00043186 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density | Low Bone Mineral Density | P2 | Completed | 412 | RCT, Double-blind | Placebo, Denosumab, Alendronate |
| NCT00586443 BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) | Solid Tumors | P1 | Completed | 56 | Open-label | bevacizumab, everolimus, panitumumab |
| NCT01789242 A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis | Amyloidosis, Systemic Light Chain Amyloidosis | P1 | Completed | 32 | Open-label | Carfilzomib, Dexamethasone |
| NCT05480865 SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | Solid Tumor, Adult, Metastatic Solid Tumor | P1 | Terminated | 28 | RCT, Open-label | BBP-398, sotorasib |
| NCT01549431 Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Completed | 32 | Open-label | Panobinostat, Carfilzomib, Dexamethasone |
| NCT00986895 A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group | Hepatic Encephalopathy, Urea Cycle Disorders | P1 | Completed | 32 | Open-label | HPN-100 |
| NCT00007813 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor | P1 | Completed | 21 | Open-label | filgrastim, carboplatin, cyclophosphamide, etoposide |
| NCT00879385 KRAS Wild-type Metastatic Colorectal Cancer Trial | Colorectal Cancer | P1 | Completed | 21 | Open-label | Dacogen™ (decitabine), Vectibix® (panitumumab) |
| NCT04293094 Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 66 | Open-label | AMG 650 |
| NCT03797261 A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma | P1 | Terminated | 9 | Open-label | Venetoclax, AMG 176 |
| NCT00977600 A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) | Healthy | P1 | Completed | 24 | RCT, Open-label | HPN-100, Ammonul, Buphenyl |
| NCT01660750 A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma | Multiple Myeloma | P1 | Completed | 29 | Open-label | Carfilzomib, Cyclophosphamide, Dexamethasone |
| NCT01124279 Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 43 | RCT, Open-label | AMG 853 |
| NCT03276728 Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients | Heart Failure, Healthy Volunteer | P1 | Terminated | 182 | RCT, Double-blind | AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV |
| NCT01101048 An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density | Osteopenia | P1 | Completed | 74 | RCT, Double-blind | Placebo, AMG 167 |
| NCT04524455 Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | Acute Lymphoblastic Leukemia | P1 | Completed | 17 | Open-label | Blinatumomab, AMG 404, Dexamethasone Premedication |
| NCT03541369 Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia (AML) | P1 | Terminated | 64 | Open-label | AMG 427 |
| NCT02244112 A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies | Advanced Non-Central Nervous System (CNS) Malignancies | P1 | Terminated | 43 | Open-label | Oprozomib, Midazolam |
| NCT01331941 A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function | Advanced Solid Tumors, Kidney Disease | P1 | Completed | 35 | Open-label | AMG 386 + Paclitaxel, AMG 386 |
| NCT06389578 A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease | Thyroid Eye Disease | P1 | Completed | 16 | RCT, Open-label | Teprotumumab |
| NCT06352892 A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight | Obesity | P1 | Completed | 20 | RCT, Open-label | Maridebart Cafraglutide |
| NCT02291614 A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer | GI Adenocarcinoma | P1 | Terminated | 45 | Open-label | AMG 211 |
| NCT00757042 Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis | Atopic Dermatitis, Healthy Volunteers | P1 | Completed | 78 | RCT, Double-blind | Tezepelumab, Placebo |
| NCT00040651 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients | Scleroderma, Systemic Sclerosis | P1 | Terminated | 15 | Open-label | Fludarabine, Cyclophosphamide, Thymoglobulin |
| NCT01135680 Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 | Drug Toxicity | P1 | Completed | 98 | RCT, Double-blind | HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin, HPN-100, HPN-100 |
| NCT02053753 Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product | Healthy Volunteer | P1 | Completed | 146 | RCT, Double-blind | Denosumab CP4, Denosumab CP2 |
| NCT01290029 Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | Chronic Kidney Disease, Hyperparathyroidism, Secondary | P1 | Completed | 14 | Open-label | Cinacalcet |
| NCT04727554 Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 11 | Open-label | AMG 994, AMG 404 |
| NCT05988034 A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants | Electrocardiography | P1 | Completed | 58 | RCT, Double-blind | Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin |
| NCT02641353 Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension | Healthy Volunteers | P1 | Completed | 34 | RCT, Open-label | Apremilast Tablet, Apremilast Oral Suspension |
| NCT03822078 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women | Osteoporosis | P1 | Completed | 45 | RCT, Double-blind | Placebo, Denosumab |
| NCT07283640 A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia | Blinatumomab, Revumenib | P1 | Not Yet Recruiting | 20 | Open-label | Revumenib, Blinatumomab |
| NCT03626662 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a) | Cardiovascular Disease | P1 | Completed | 79 | RCT, Double-blind | AMG 890, Placebo |
| NCT05578859 A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects | Healthy Subjects | P1 | Completed | 8 | Open-label | AMG 510 |
| NCT02269085 Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | Lymphoma | P1 | Terminated | 8 | Open-label | Ibrutinib, Carfilzomib |
| NCT06004960 A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | P1 | Completed | 6 | Open-label | [14C]CCX168 |
| NCT01059435 A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women | Osteopenia | P1 | Completed | 74 | RCT, Double-blind | Romosozumab, Placebo |
| NCT01428154 Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease | Anemia, Chronic Kidney Disease | P1 | Withdrawn | — | Open-label | Darbepoetin alfa |
| NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma | P1 | Completed | 48 | Open-label | Carfilzomib, Dexamethasone |
| NCT02561962 A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Completed | 42 | Open-label | AMG 224 |
| NCT04857606 Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease | Non-alcoholic Fatty Liver Disease | P1 | Completed | 47 | RCT, Double-blind | AMG 609, Placebo |
| NCT02512926 Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | Relapsed Solid Tumors, Refractory Solid Tumors | P1 | Completed | 4 | Open-label | Carfilzomib, Cyclophosphamide, Etoposide |
| NCT02780674 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases | Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc | P1 | Completed | 36 | RCT, Double-blind | MEDI7734, Placebo |
| NCT01791374 Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ | Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer | P1 | Completed | 21 | Open-label | Rilotumumab, Rilotumumab |
| NCT00950950 A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass | Osteopenia | P1 | Completed | 24 | RCT, Double-blind | Romosozumab, Placebo |
| NCT02103283 A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) | Diabetic Macular Edema | P1 | Completed | 5 | Open-label | Teprotumumab |
| NCT05317078 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer | P1 | Terminated | 3 | Open-label | AMG 794 |
| NCT03554044 T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | P1 | Completed | 20 | Open-label | Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin |
| NCT02802735 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects | Pharmacokinetics | P1 | Completed | 28 | RCT, Open-label | Apremilast, Placebo |
| NCT01555268 Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | P1 | Completed | 24 | Open-label | trebananib, cytarabine |
| NCT03156023 Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 34 | RCT, Double-blind | Rozibafusp Alfa, Placebo |
| NCT03088176 Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | Melanoma, BRAF Gene Mutation | P1 | Unknown | 4 | Open-label | Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Trametinib |
| NCT01493518 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis | Psoriasis | P1 | Terminated | 6 | RCT, Double-blind | AMG 557 or PLACEBO |
| NCT02777554 A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults | Healthy Volunteers | P1 | Completed | 144 | RCT, Open-label | Apremilast IR, Apremilast XL |
| NCT06563856 A Study of TEPEZZA Subcutaneous Administration in Healthy Adults | Bioavailability, Bioequivalence | P1 | Completed | 37 | Open-label | TEPEZZA, EDP |
| NCT00997022 Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | Hepatocellular Cancer | P1 | Completed | 14 | Open-label | Sorafenib |
| NCT00448786 Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors | Solid Tumors | P1 | Completed | 49 | RCT, Open-label | AMG 706, AMG 706, AMG 706 |
| NCT06468826 A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) | End-Stage Renal Disease (ESRD) | P1 | Completed | 13 | Open-label | Avacopan |
| NCT02391259 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P1 | Completed | 57 | RCT, Double-blind | AMG 557, Placebo |
| NCT05550129 Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants | Healthy Volunteers | P1 | Completed | 13 | Open-label | AMG 510, Metformin |
| NCT03751709 Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult | P1 | Completed | 22 | Open-label | Blinatumomab |
| NCT02437916 Safety Study of AMG 228 to Treat Solid Tumors | Advanced Malignancy, Advanced Solid Tumors | P1 | Terminated | 30 | Open-label | AMG 228 |
| NCT01755442 Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects | Diabetes Mellitus | P1 | Terminated | 5 | RCT, Double-blind | AMG 151 |
| NCT01380756 Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | Cancer, Hematologic Malignancies | P1 | Completed | 35 | Open-label | Arm 1- Dose Escalation, Arm 2- Dose Expansion |
| NCT05045638 Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants | Healthy Participants | P1 | Completed | 13 | Open-label | Rosuvastatin, Sotorasib |
| NCT05327491 A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets | Healthy Participants | P1 | Completed | 146 | RCT, Open-label | Sotorasib |
| NCT07428525 A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function | Hepatic Impairment | P1 | Completed | 36 | Open-label | AMG 133 |
| NCT00563316 Effect of Panitumumab on the Pharmacokinetics of Irinotecan | Metastatic Colorectal Cancer | P1 | Completed | 28 | Open-label | Panitumumab, Irinotecan |
| NCT06004947 A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | P1 | Completed | 32 | Open-label | CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin |
| NCT02499315 Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Terminated | 32 | RCT, Double-blind | AMG 357, Placebo |
| NCT03989544 A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects | Asthma | P1 | Completed | 315 | RCT, Open-label | Tezepelumab |
| NCT05481411 A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment | Hepatic Impairment | P1 | Completed | 25 | Open-label | Olpasiran |
| NCT02741310 Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan | Healthy Subjects | P1 | Completed | 34 | RCT, Double-blind | Placebo, Sumatriptan, Erenumab |
| NCT06207682 Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin | Healthy Volunteers | P1 | Completed | 32 | RCT, Open-label | Avacopan, Simvastatin |
| NCT01688739 Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients | Migraine | P1 | Completed | 61 | RCT, Double-blind | Erenumab, Placebo |
| NCT04998747 A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Relapsed/Refractory Multiple Myeloma | P1 | Withdrawn | — | Open-label | AMG 701, AMG 701 |
| NCT00274742 Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | Non-Hodgkin's Lymphoma, Relapsed | P1 | Completed | 76 | Open-label | Blinatumomab (MT103) |
| NCT04702737 A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Neuroendocrine Prostate Cancer | P1 | Completed | 41 | Open-label | Tarlatamab |
| NCT05599828 A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants | Healthy Participants | P1 | Completed | 14 | Open-label | AMG 510, Omeprazole, Famotidine |
| NCT00503490 Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis | Cystic Fibrosis | P1 | Completed | 40 | RCT, Single-blind | MP-376 (Levofloxacin solution for Inhalation), placebo |
| NCT01497821 AMG 172 First in Human Study in Patients With Kidney Cancer | Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma | P1 | Completed | 37 | Open-label | AMG 172 |
| NCT02833857 A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis | Chronic Kidney Disease, Secondary Hyperparathyroidism | P1 | Completed | 11 | Open-label | Etelcalcetide |
| NCT05267470 A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) | Squamous-Cell Non-Small-Cell Lung Cancer | P1 | Terminated | 74 | Open-label | Bemarituzumab, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel |
| NCT01999335 A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma | Multiple Myeloma | P1 | Terminated | 33 | Open-label | Oprozomib, Pomalidomide, Dexamethasone |
| NCT00562380 AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma | Lymphoma, Prostate Cancer | P1 | Completed | 64 | RCT, Open-label | ganitumab |
| NCT00752414 A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic Obstructive Pulmonary Disease | P1 | Completed | 21 | RCT, Single-blind | MP-376 (Levofloxacin solution for Inhalation), Placebo |
| NCT05577624 A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants | Healthy Participants | P1 | Completed | 14 | Open-label | AMG 510, Rifampin |
| NCT03451422 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P1 | Completed | 35 | RCT, Double-blind | Efavaleukin Alfa, Placebo |
| NCT04740034 A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | P1 | Terminated | 42 | Open-label | AMG 340 |
| NCT03170193 AMG 529 First in Human Study | Cardiovascular | P1 | Completed | 48 | RCT, Double-blind | AMG 529, Placebo |
| NCT00858377 A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | Advanced Malignancy, Advanced Solid Tumors | P1 | Completed | 95 | Open-label | Arm 1- Dose Escalation, Arm 1- Dose Expansion |
| NCT01389895 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus, Lupus | P1 | Terminated | 1 | RCT, Double-blind | AMG 557, AMG 557 Placebo |
| NCT01738594 Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | P1 | Terminated | 7 | RCT, Open-label | carfilzomib, romidepsin |
| NCT00361634 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 14 | Open-label | Etanercept |
| NCT01869686 Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose | Healthy Volunteer | P1 | Completed | 12 | Open-label | Denosumab |
| NCT04822298 Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer, NSCLC | P1 | Terminated | 3 | Open-label | AMG 160 |
| NCT02132429 Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects | Migraine | P1 | Terminated | 16 | RCT, Double-blind | AMG 333, Placebo |
| NCT04478994 A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) | Diffuse Cutaneous Systemic Sclerosis | P1 | Terminated | 3 | RCT, Double-blind | TEPEZZA |
| NCT00101894 Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer | Rectal Cancer, Colon Cancer | P1 | Completed | 119 | Open-label | FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI |
| NCT02504476 Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective | Schizophrenia or Schizoaffective Disorder | P1 | Completed | 52 | RCT, Double-blind | AMG 581, Placebo, Midazolam |
| NCT03904069 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Relapsed/Refractory Acute Myeloid Leukemia | P1 | Withdrawn | — | Open-label | AMG 553 |
| NCT01212380 Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer | P1 | Completed | 21 | Open-label | carfilzomib |
| NCT05245851 Clinical Deployment and Validation of Rho | Low Bone Density | N/A | Completed | 1,146 | Open-label | — |
| NCT01139918 Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis | Psoriatic Arthritis, Psoriasis | Completed | 105 | — | — | |
| NCT05347745 Therascreen® KRAS RGQ PCR Kit | Colo-rectal Cancer | N/A | Completed | 219 | Open-label | — |
| NCT02520362 Denosumab Safety Assessment in Multiple Observational Databases | Osteoporosis | Completed | 517,991 | — | denosumab, bisphosphonate | |
| NCT05826756 Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting | Lung Cancer Patients, Caregivers | Unknown | 1,300 | — | — | |
| NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | Metastatic Nonsmall Cell Lung Cancer | Completed | 851 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT02922179 Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics | Diabetes | Completed | 103,951 | — | Long- and intermediate- acting insulins | |
| NCT05348187 Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit | Non-Small Cell Lung Cancer, Colorectal Cancer | N/A | Completed | 309 | Open-label | — |
| NCT05347797 Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit | Non-small Cell Lung Cancer | N/A | Completed | 495 | Open-label | — |
| NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | Metastatic Non Small Cell Lung Cancer | Completed | 304 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | Metastatic Breast Cancer | Completed | 724 | — | Palbociclib, Letrozole | |
| NCT05360225 Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit | Non Small Cell Lung Cancer | Completed | 5,000 | — | — | |
| NCT00186602 Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer? | Breast Cancer | Completed | — | — | — | |
| NCT02922192 Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis | Rheumatoid Arthritis, Inflammatory Bowel Disease | Completed | 90,360 | — | TNF-α antagonists, non-TNFs, DMARD non-biologics | |
| NCT02921191 Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated | Breast Cancer, Lung Cancer | Completed | 57,725 | — | filgrastim, TBO-filgrastim or pegfilgrastim | |
| NCT02185911 Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis | Anaemia, Chronic Kidney Disease (CKD) | Completed | 308 | — | — | |
| NCT00418743 Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer | Unknown | 138 | — | — | |
| NCT02537535 Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada | Dyslipidemia | Completed | 2,027 | — | — | |
| NCT00322439 Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis | Psoriasis | Completed | 2,511 | — | Etanercept | |
| NCT03398954 a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia | Familial Hypercholesterolemia | Unknown | 1,128 | — | — | |
| NCT01668589 Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | Completed | 1,501 | — | — | |
| NCT02178475 Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy | Chemotherapy-induced Febrile Neutropenia | Completed | 943 | — | — | |
| NCT02875184 A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands | Arthritis, Psoriatic | Completed | 200 | — | — | |
| NCT02740218 A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice | Psoriasis | Completed | 610 | — | — | |
| NCT01997892 TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta | Anemia | Completed | 1,027 | — | — | |
| NCT02287610 A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Completed | 75 | — | RAYOS (delayed-release prednisone) | |
| NCT03780504 Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece | Psoriatic Arthritis | Unknown | 170 | — | — | |
| NCT02976818 Lp(a) and Aortic Valve Calcification | Heterozygous Familial Hypercholesterolemia | Completed | 173 | — | — | |
| NCT01936376 A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers | Head and Neck Cancer | Unknown | 150 | — | — | |
| NCT00094822 Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) | Lung Cancer, Non-Small Cell Lung Cancer | Completed | 90 | — | — | |
| NCT03117621 Observational Study of Blinatumomab | Blincyto Use in Routine Clinical Practice | Completed | 279 | — | — | |
| NCT01015625 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer | Synchronous Metastasized Breast Cancer, Circulating Tumor Cells | N/A | Completed | 90 | RCT, Open-label | — |
| NCT03812367 Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid | Osteoporosis, Postmenopausal | Withdrawn | — | — | — | |
| NCT03139630 COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients | HIV Seropositivity, Dyslipidemias | Completed | 193 | — | — | |
| NCT00501228 Tissue Repair in Stem Cell Transplant Recipients | Graft-Versus-Host Disease | N/A | Terminated | 2 | Open-label | Filgrastim |
| NCT01710722 The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man | Obesity | N/A | Completed | 45 | RCT, Double-blind | caffeine and ephedrine, Leptin A, caffeine, ephedrine, and leptin A |
| NCT00949546 Treatment of Hidradenitis Suppurativa Using Etanercept | Hidradenitis Suppurativa | Completed | 20 | — | etanercept | |
| NCT01948427 Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) | Urea Cycle Disorder | Terminated | 203 | — | — | |
| NCT00116727 Rheumatoid Arthritis DMARD Intervention and UtilizationStudy | Rheumatoid Arthritis | Completed | 5,103 | — | ENBREL® | |
| NCT03469661 Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) | Immune Thrombocytopenia, Myelodysplastic Syndromes | Completed | 63 | — | — | |
| NCT00454857 Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | Completed | 326 | — | — | |
| NCT01791361 Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe | Metastatic Colorectal Cancer | Completed | 439 | — | — | |
| NCT00617370 Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | Breast Cancer, Adenocarcinoma of the Breast | N/A | Completed | 38 | Open-label | epirubicin, cyclophosphamide, Paclitaxel, |
| NCT00300001 Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes | Cancer, Solid Tumor | Unknown | 300 | — | — | |
| NCT00838097 European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa | Chronic Kidney Disease | Completed | 321 | — | — | |
| NCT01967160 Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid | Osteonecrosis of the Jaw, Infection Leading to Hospitalization | Completed | 2,560 | — | — | |
| NCT01998607 Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw | Solid Tumours, Bone Metastasis | Completed | 420 | — | — | |
| NCT02173171 Registry Study for Talimogene Laherparepvec | Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial | Completed | 185 | — | — | |
| NCT02957604 Evolocumab Pregnancy Exposure Registry | Hypercholesterolemia; ASCVD; Pregnancy | Terminated | 140 | — | evolocumab | |
| NCT03970902 Quality of Life in Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | Completed | 239 | — | — | |
| NCT05378529 A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) | Atherosclerotic Cardiovascular Disease | N/A | Completed | 39,480 | Open-label | — |
| NCT01813721 Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy. | Chemotherapy-induced Febrile Neutropenia | Completed | 1,007 | — | — | |
| NCT03620188 Treatment Goals in Psoriatic Arthritis | Psoriatic Arthritis | Completed | 250 | — | — | |
| NCT00355407 Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | Hematologic Malignancies | N/A | Completed | 31 | Open-label | Darbepoetin alfa |
| NCT02085993 Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training | Immune Thrombocytopenic Purpura | Completed | 41 | — | — | |
| NCT02808403 Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan | Hypercholesterolemia, Familial Hypercholesterolemia | Completed | 6,000 | — | — | |
| NCT00903812 IMPACT Non Hodgkins Lymphoma (NHL) Study | Non-Hodgkin's Lymphoma | Completed | 1,837 | — | — | |
| NCT04197453 The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS) | ASCVD | Terminated | 752 | — | — | |
| NCT02770131 Chart Review of Repatha® in Subjects With Hyperlipidaemia | Hypercholesterolaemia | Completed | 1,986 | — | — | |
| NCT03751072 Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO) | Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Completed | 92 | — | — | |
| NCT00189501 A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD) | Nephrology | Completed | 1,000 | — | Sensipar® | |
| NCT06081153 Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | Abdominal Aortic Aneurysm | Early P1 | Not Yet Recruiting | 44 | RCT, Double-blind | Evolocumab, Placebo |
| NCT06590051 AMG 335 Expanded Access Program for IgG4-Related Disease | AVAILABLE | — | — | UPLIZNA | ||
| NCT03224819 Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Early P1 | Terminated | 46 | Open-label | Emerfetamab |
| NCT05885607 Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure | Heart Failure NYHA Class II, Heart Failure NYHA Class III | By Invite | 40 | — | — | |
| NCT02322736 Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR | Metastatic Colorectal Cancer | Completed | 218 | — | — | |
| NCT00283621 Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide | Sarcoma | N/A | Completed | 51 | Open-label | Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide |
| NCT04386629 Health Economy Register | Breast Neoplasms | Completed | 219 | — | — | |
| NCT07085117 Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients | Thyroid Eye Disease | Completed | 5 | — | Teprotumumab | |
| NCT02993120 Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States | Medical Conditions to be Studied, Dyslipidemia | Completed | 5,006 | — | — | |
| NCT00704652 Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus | Diabetic Retinopathy | Terminated | 5 | — | — | |
| NCT06064500 Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | Small Cell Lung Cancer | APPROVED_FOR_MARKETING | — | — | Tarlatamab | |
| NCT02273570 Optimal Anemia Treatment in End Stage Renal Disease (ERSD) | Hyperparathyroidism, Secondary | N/A | Unknown | 50 | RCT, Open-label | standard care, Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D |
| NCT00116714 Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy | Rheumatoid Arthritis | Completed | 4,968 | — | DMARD | |
| NCT02066805 Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark | XGEVA Off-label Use | Completed | 142 | — | Database assessment of off-label XGEVA use | |
| NCT03106051 Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions | Arthritis, Psoriatic | Completed | 526 | — | — | |
| NCT06761703 A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss | Obesity | Completed | 200 | — | — |